Cereno Scientific strengthens its organization and engages a Chief Medical Officer before the start of a phase II study with CS113 September, 2018
Cereno Scientific announces today that the company engages Björn Dahlöf as Chief Medical Officer (CMO). Dahlöf, who is a Board member and principal owner, has extensive experience in cardiovascular research, pharmacology, drug development and clinical testing in all phases, and has lectured internationally in these fields.
“I have had the privilege of working with Björn Dahlöf for four years, and it is gratifying for us to link him more closely with Cereno’s development work. Björn is a global key opinion leader, and his extensive experience in drug development and international network of contacts will be very valuable for upcoming clinical studies,” says Sten R. Sörensen, CEO of Cereno Scientific.
Cereno Scientific is developing the drug candidate CS1, a new preventive medicine against blood clots. In earlier preclinical and clinical studies, the company returned positive results in terms of safety, pharmacokinetic properties and effect on biomarkers for the risk of thrombosis. In addition to the normalizing effects on t-PA production, administering the active substance in CS1 also results in a reduction of PAI-1 levels, where PAI is an important risk factor for thrombosis formation. The company recently signed an agreement with OCT Group to initiate a phase II study to investigate the antithrombotic effects of CS1.
“Cereno Scientific is at a very exciting stage, with an imminent phase II study and convincing data from all its studies in its possession. I look forward to expanding my involvement and to driving the development of CS1 towards commercialization,” says Björn Dahlöf, Cereno Scientific’s newly appointed CMO.
Björn Dahlöf is a licensed physician and has been practicing general internal medicine at Sahlgrenska University Hospital for over 35 years. He is also associate professor in cardiovascular prevention at Sahlgrenska Academy in the University of Gothenburg. He has been an adviser for drug development in cardiovascular prevention for a number of drug companies both large and small, and has initiated and conducted a great number of outcome studies in cardiovascular prevention. He has also published over 400 scientific works in reputable scientific journals, and is among the most published researchers in Sweden. In addition, Dahlöf has experience in starting up and running smaller companies in drug development and clinical trial monitoring.
About Cereno Scientific AB
Cereno Scientific is developing a novel preventive medicine to treat thrombosis-related disease, based on the body’s own intelligent clot-busting system. Cardiovascular disease is currently the leading cause of death worldwide. Current therapies are connected to an increased risk of bleeding and, as a result, low effectiveness due to lower dosing levels. In turn, this leads to a high risk of new blood clots. Cereno Scientific’s drug candidate, CS1, is expected to provide a possibility for an effective prevention of thrombosis and a lower risk for serious bleeding complications than with current blood thinning therapies. CS1 is an innovative controlled release formulation of a known compound and, as such, is expected to have a relatively short development time. The Gothenburg-based company is located in AstraZeneca’s BioVentureHub and is supported by GU Ventures. Cereno Scientific’s B share has been listed on Spotlight Stock Market since June 2016 with the ticker CRNO B, ISIN SE0008241558.
This information is such that Cereno Scientific AB is required to make public in accordance with the EU’s market abuse regulation (MAR). The information was made available publically by the Company’s contact person on September 13th 2018.